BACKGROUND: The poor prognosis of rheumatoid arthritis (RA) can be aggravated by the concomitant presence of chronic hepatitis C virus (HCV) infection and there are no guidelines for the treatment of patients affected by both conditions.OBJECTIVE: To propose new therapeutic strategies for patient affected by RA and concomitant HCV chronic infection.METHODS: Review of the literature on the usage of cyclosporine-A (CsA) and anti-tumour-necrosis-factor (TNF)-alpha agents for the treatment of patients affected by RA and HCV.RESULTS/CONCLUSION: CsA exerts an inhibitory effect on HCV replication and it is safe in patients affected by RA and HCV. Anti-TNF-alpha agents are safe and efficacious in patient with RA and HCV. Anti-TNF-alpha and CsA can be safely given in combination in RA patients with HCV infection.

Treatment strategies for a patient with rheumatoid arthritis and hepatitis C / Giannitti, C; Bellisai, F; Ferri, Clodoveo; Galeazzi, M.. - In: EXPERT OPINION ON PHARMACOTHERAPY. - ISSN 1465-6566. - STAMPA. - 10:(2009), pp. 579-587.

Treatment strategies for a patient with rheumatoid arthritis and hepatitis C.

FERRI, Clodoveo;
2009

Abstract

BACKGROUND: The poor prognosis of rheumatoid arthritis (RA) can be aggravated by the concomitant presence of chronic hepatitis C virus (HCV) infection and there are no guidelines for the treatment of patients affected by both conditions.OBJECTIVE: To propose new therapeutic strategies for patient affected by RA and concomitant HCV chronic infection.METHODS: Review of the literature on the usage of cyclosporine-A (CsA) and anti-tumour-necrosis-factor (TNF)-alpha agents for the treatment of patients affected by RA and HCV.RESULTS/CONCLUSION: CsA exerts an inhibitory effect on HCV replication and it is safe in patients affected by RA and HCV. Anti-TNF-alpha agents are safe and efficacious in patient with RA and HCV. Anti-TNF-alpha and CsA can be safely given in combination in RA patients with HCV infection.
10
579
587
Treatment strategies for a patient with rheumatoid arthritis and hepatitis C / Giannitti, C; Bellisai, F; Ferri, Clodoveo; Galeazzi, M.. - In: EXPERT OPINION ON PHARMACOTHERAPY. - ISSN 1465-6566. - STAMPA. - 10:(2009), pp. 579-587.
Giannitti, C; Bellisai, F; Ferri, Clodoveo; Galeazzi, M.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11380/646420
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 11
  • ???jsp.display-item.citation.isi??? 7
social impact